Cargando…

Real-world effectiveness of osteoporosis treatment in the oldest old

SUMMARY: We studied effectiveness of osteoporosis treatment in women older than 80 years, who often are not included in clinical trials. Treatments were as effective on bone density and fractures as in younger women. INTRODUCTION: To study real-world effectiveness of osteoporosis treatment on BMD an...

Descripción completa

Detalles Bibliográficos
Autores principales: Ström, O., Lauppe, R., Ljunggren, Ö., Spångéus, A., Ortsäter, G., O’Kelly, J., Åkesson, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360659/
https://www.ncbi.nlm.nih.gov/pubmed/32232509
http://dx.doi.org/10.1007/s00198-020-05380-6
_version_ 1783559255403528192
author Ström, O.
Lauppe, R.
Ljunggren, Ö.
Spångéus, A.
Ortsäter, G.
O’Kelly, J.
Åkesson, K.
author_facet Ström, O.
Lauppe, R.
Ljunggren, Ö.
Spångéus, A.
Ortsäter, G.
O’Kelly, J.
Åkesson, K.
author_sort Ström, O.
collection PubMed
description SUMMARY: We studied effectiveness of osteoporosis treatment in women older than 80 years, who often are not included in clinical trials. Treatments were as effective on bone density and fractures as in younger women. INTRODUCTION: To study real-world effectiveness of osteoporosis treatment on BMD and fractures in the oldest old women (≥ 80 years) compared with women (60–79 years) in the clinical setting using Swedish health register data. METHODS: National registers and data from DXA machines were used to study effectiveness of all available osteoporosis treatments in women 60–79 and ≥ 80 years using three approaches: (1) Total Hip BMD change up to 8 years after treatment start; (2) fracture incidence where patients served as their own controls, comparing the first 3 months after treatment start with the subsequent 12 months; and (3) comparison of fracture incidence post-fracture in women ≥ 80 years treated with osteoporosis treatment or calcium/vitamin D. RESULTS: Analysis 1: Total Hip BMD increased by up to 6.7% and 7.7% in women 60–79 and ≥ 80 years old, respectively. The mean increase in BMD was 1.1%-units per year in both age groups. Analysis 2: Relative to the 3-month baseline, fracture incidence decreased during the subsequent 12 months of treatment. Incidence rate ratios were estimated at 0.65, 0.74, 0.29, and 0.81 for any, hip, vertebral, and non-hip-non-vertebral fracture, respectively. Analysis 3: A 24-month incidence of any fracture in women ≥ 80 years given post-fracture osteoporosis treatment was lower (HR = 0.78) than in women given calcium/vitamin D, but treatment allocation was not random, with lower mortality (HR = 0.51) in patients receiving OP treatment. CONCLUSIONS: Osteoporosis medication in women > 80 years in clinical practice likely works, and the magnitude of effect is similar to what was estimated in younger women. The choice between osteoporosis treatment and calcium/vitamin D after fracture in women ≥ 80 years is not random but appears associated with the patient’s health status and presence of vertebral fractures, rather than the known risk profile of sustaining a fracture at a high age. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00198-020-05380-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7360659
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer London
record_format MEDLINE/PubMed
spelling pubmed-73606592020-07-16 Real-world effectiveness of osteoporosis treatment in the oldest old Ström, O. Lauppe, R. Ljunggren, Ö. Spångéus, A. Ortsäter, G. O’Kelly, J. Åkesson, K. Osteoporos Int Original Article SUMMARY: We studied effectiveness of osteoporosis treatment in women older than 80 years, who often are not included in clinical trials. Treatments were as effective on bone density and fractures as in younger women. INTRODUCTION: To study real-world effectiveness of osteoporosis treatment on BMD and fractures in the oldest old women (≥ 80 years) compared with women (60–79 years) in the clinical setting using Swedish health register data. METHODS: National registers and data from DXA machines were used to study effectiveness of all available osteoporosis treatments in women 60–79 and ≥ 80 years using three approaches: (1) Total Hip BMD change up to 8 years after treatment start; (2) fracture incidence where patients served as their own controls, comparing the first 3 months after treatment start with the subsequent 12 months; and (3) comparison of fracture incidence post-fracture in women ≥ 80 years treated with osteoporosis treatment or calcium/vitamin D. RESULTS: Analysis 1: Total Hip BMD increased by up to 6.7% and 7.7% in women 60–79 and ≥ 80 years old, respectively. The mean increase in BMD was 1.1%-units per year in both age groups. Analysis 2: Relative to the 3-month baseline, fracture incidence decreased during the subsequent 12 months of treatment. Incidence rate ratios were estimated at 0.65, 0.74, 0.29, and 0.81 for any, hip, vertebral, and non-hip-non-vertebral fracture, respectively. Analysis 3: A 24-month incidence of any fracture in women ≥ 80 years given post-fracture osteoporosis treatment was lower (HR = 0.78) than in women given calcium/vitamin D, but treatment allocation was not random, with lower mortality (HR = 0.51) in patients receiving OP treatment. CONCLUSIONS: Osteoporosis medication in women > 80 years in clinical practice likely works, and the magnitude of effect is similar to what was estimated in younger women. The choice between osteoporosis treatment and calcium/vitamin D after fracture in women ≥ 80 years is not random but appears associated with the patient’s health status and presence of vertebral fractures, rather than the known risk profile of sustaining a fracture at a high age. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00198-020-05380-6) contains supplementary material, which is available to authorized users. Springer London 2020-03-30 2020 /pmc/articles/PMC7360659/ /pubmed/32232509 http://dx.doi.org/10.1007/s00198-020-05380-6 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Original Article
Ström, O.
Lauppe, R.
Ljunggren, Ö.
Spångéus, A.
Ortsäter, G.
O’Kelly, J.
Åkesson, K.
Real-world effectiveness of osteoporosis treatment in the oldest old
title Real-world effectiveness of osteoporosis treatment in the oldest old
title_full Real-world effectiveness of osteoporosis treatment in the oldest old
title_fullStr Real-world effectiveness of osteoporosis treatment in the oldest old
title_full_unstemmed Real-world effectiveness of osteoporosis treatment in the oldest old
title_short Real-world effectiveness of osteoporosis treatment in the oldest old
title_sort real-world effectiveness of osteoporosis treatment in the oldest old
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360659/
https://www.ncbi.nlm.nih.gov/pubmed/32232509
http://dx.doi.org/10.1007/s00198-020-05380-6
work_keys_str_mv AT stromo realworldeffectivenessofosteoporosistreatmentintheoldestold
AT laupper realworldeffectivenessofosteoporosistreatmentintheoldestold
AT ljunggreno realworldeffectivenessofosteoporosistreatmentintheoldestold
AT spangeusa realworldeffectivenessofosteoporosistreatmentintheoldestold
AT ortsaterg realworldeffectivenessofosteoporosistreatmentintheoldestold
AT okellyj realworldeffectivenessofosteoporosistreatmentintheoldestold
AT akessonk realworldeffectivenessofosteoporosistreatmentintheoldestold